Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1997 Jul;73(861):409–411. doi: 10.1136/pgmj.73.861.409

The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice.

C G Missouris 1, G A MacGregor 1
PMCID: PMC2431408  PMID: 9338025

Abstract

Several well-controlled trials in patients with heart failure have shown that the use of angiotensin-converting enzyme (ACE) inhibitors, in combination with a diuretic, causes a reduction in mortality and morbidity, which seems to be mainly due to a reduction in fatal and nonfatal cardiovascular events. Our aim was to determine whether 249 consecutive patients discharged from hospital with a primary diagnosis of heart failure were routinely being treated with an ACE inhibitor at an appropriate dose. At the time of admission to hospital, 91 (36.5%) were receiving a combination of a diuretic and an ACE inhibitor, 129 (51.8%) were receiving a diuretic alone, and 29 (11.6%) had not previously received either a diuretic or an ACE inhibitor. At the time of discharge from hospital all patients were on a diuretic and 144 (57.8%) were also receiving an ACE inhibitor. Although 41 patients (16.5%) had a relative or absolute contraindication for the use of an ACE inhibitor, 64 patients (25.7%) with no contraindication were not receiving an ACE inhibitor. Many of the patients who were prescribed an ACE inhibitor were given it at an inappropriate dose; only 24 patients (16.7%) were on the dose that was used in the clinical trials showing a reduction in mortality. These results show that in one in four patients admitted to hospital with heart failure who should be receiving an ACE inhibitor by the time of discharge, are not. The average age of these patients was 76 years. Whilst it has been shown that the benefit of ACE inhibitors does not appear to be age-related, most published studies have not included many patients over the age of 80. Specific studies looking at the effect of ACE inhibitors in elderly patients would be helpful, as well as studies to determine the optimum treatment regimen for this age group.

Full text

PDF
409

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bath P. M., Prasad A., Brown M. M., MacGregor G. A. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ. 1993 Oct 23;307(6911):1045–1045. doi: 10.1136/bmj.307.6911.1045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark A. L., Coats A. J. Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. BMJ. 1995 Apr 15;310(6985):973–974. doi: 10.1136/bmj.310.6985.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dargie H. J., McMurray J. J. Diagnosis and management of heart failure. BMJ. 1994 Jan 29;308(6924):321–328. doi: 10.1136/bmj.308.6924.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302. doi: 10.1056/NEJM199108013250501. [DOI] [PubMed] [Google Scholar]
  5. Ghali J. K., Cooper R., Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med. 1990 Apr;150(4):769–773. [PubMed] [Google Scholar]
  6. Gurwitz J. H., Goldberg R. J., Holden A., Knapic N., Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med. 1988 Aug;148(8):1733–1736. [PubMed] [Google Scholar]
  7. Kannel W. B., Belanger A. J. Epidemiology of heart failure. Am Heart J. 1991 Mar;121(3 Pt 1):951–957. doi: 10.1016/0002-8703(91)90225-7. [DOI] [PubMed] [Google Scholar]
  8. Konstam M. A., Kronenberg M. W., Rousseau M. F., Udelson J. E., Melin J., Stewart D., Dolan N., Edens T. R., Ahn S., Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993 Nov;88(5 Pt 1):2277–2283. doi: 10.1161/01.cir.88.5.2277. [DOI] [PubMed] [Google Scholar]
  9. McKee P. A., Castelli W. P., McNamara P. M., Kannel W. B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441–1446. doi: 10.1056/NEJM197112232852601. [DOI] [PubMed] [Google Scholar]
  10. McMurray J., McDonagh T., Morrison C. E., Dargie H. J. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J. 1993 Sep;14(9):1158–1162. doi: 10.1093/eurheartj/14.9.1158. [DOI] [PubMed] [Google Scholar]
  11. Petersen P., Boysen G., Godtfredsen J., Andersen E. D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989 Jan 28;1(8631):175–179. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
  12. Sutton G. C. Epidemiologic aspects of heart failure. Am Heart J. 1990 Dec;120(6 Pt 2):1538–1540. doi: 10.1016/0002-8703(90)90055-3. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES